Patients with tuberculosis (TB)
Contracted medical units in Yunlin-Chiayi-Tainan, Kaohsiung-Pingtung, and Penghu
Taiwan Centers for Disease Control (CDC)
Our hospital features a BSL-2+ (P2+) tuberculosis (TB) laboratory that meets international standards. Accredited by the Taiwan CDC as a "Contracted TB Reference Laboratory," we are a certified institution for "Second-Line Drug Susceptibility Testing (DST)" and "Latent TB Infection (LTBI)" diagnosis, serving as the primary TB referral laboratory for southern Taiwan. Furthermore, we manage the national stock and distribution of second-line anti-TB drugs. We also undertake Taiwan CDC's mobile X-ray screening projects and the film-reading services for various cities and counties, expanding our impactful reach across the entire island.
First in the nation to implement biochip rapid testing coupled with NTM (non-tuberculosis mycobacteria) genotyping.
Rapid molecular testing for TB with a turnaround time (TAT) of only 1 hour and 20 minutes from initiation to reporting.
Continuous application and maintenance of ISO 15189 medical laboratory accreditation.
Advanced utilization of molecular biology techniques for precise diagnostics.
Highly accurate detection and screening for Latent Tuberculosis Infection (LTBI).
One of the 34 nationally accredited infectious disease laboratories, accounting for a substantial 8% to 9% of the national execution volume.
Serving a total of 100 contracted medical institutions across commissioned testing regions.
Geographical distribution: 55 in Tainan City, 26 in Chiayi, 2 in Yunlin County, 6 in Kaohsiung City, 8 in Pingtung County, and 1 in Penghu County.
Entrusted by the Taiwan CDC since 2001 to provide Mycobacterium tuberculosis testing services for the Yunlin-Chiayi-Tainan, Kaohsiung-Pingtung, and Penghu regions.
From 2019 to 2025, the quality control mean values consistently fell within the established threshold ranges, demonstrating a highly stable variance.
From 2019 to 2025, our team published a total of 24 peer-reviewed medical and academic papers.
In a regional comparison among the three contracted laboratories, our institution achieved the highest volume across all testing categories.
Formulated the "Biosafety Management Regulations" in strict accordance with the Communicable Disease Control Act.
Established a Biosafety Committee to oversee and manage all biosafety-related matters.
Implemented comprehensive safety measures, including personnel training requirements, safety containment facilities, and environmental/equipment monitoring, adhering closely to BSL-2(+) laboratory containment protocols.
No applicable satisfaction indicators.
SNQ Certificate of Quality from 2019 to 2025.
"Award of Merit" in the 2020 Evidence-Based Medicine (EBM)
Competition. "Creative Excellence Award" for Health Promoting Hospitals (HPH).
Successfully achieved accreditation on January 28, 2011, with renewal accreditations granted in 2014, 2017, 2020, and 2025.
Organize annual TB research and examination seminars to promote and advance TB laboratory testing capabilities.
Actively participate in Taiwan CDC quality meetings (held semi-annually) and cooperative field inspections to exchange expertise in TB testing quality control.
Assist in public-funded "Dengue NS1 Antigen Rapid Diagnostic Test" screening initiatives.
